The brief

Analyst view

• Shield is the first FDA-approved blood test for colorectal cancer screening, with 83% sensitivity.
• Q2 2026: 66k tests, $52.9M revenue, 2026 guidance $218-230M.
• American Cancer Society, UnitedHealth (40M members), and Medicare cover Shield.

Technical approach

As reported

Blood-based detection

Liquid biopsy

Shield isolates cancer DNA from blood and looks for methylation patterns. Avoids colonoscopy's pain and prep.

Residual disease

Post-treatment monitoring

Reveal detects tumor DNA after surgery or chemo to spot recurrence early. >100% volume growth in 2026.

Broad oncology

Multi-cancer DNA testing

Guardant360 detects circulating tumor DNA across cancers for treatment selection.